Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease.
Chan W, Lynch N, Bampton P, Chang J, Chung A, Florin T, Hetzel DJ, Jakobovits S, Moore G, Pavli P, Radford-Smith G, Thin L, Baraty B, Haifer C, Yau Y, Leong RWL.
Chan W, et al. Among authors: hetzel dj.
Eur J Gastroenterol Hepatol. 2018 Jul;30(7):735-740. doi: 10.1097/MEG.0000000000001150.
Eur J Gastroenterol Hepatol. 2018.
PMID: 29727386